Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma

Tamoxifen, an endocrine therapy drug used to treat breast cancer, is designed to interrupt estrogen signaling by blocking the estrogen receptor (ER). However, many ER-positive patients are low reactive or resistant to tamoxifen.